prizloncabtagene autoleucel

{
  "id": "MLC-T-ONC-016220",
  "term": "prizloncabtagene autoleucel",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes engineered to express a second-generation chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, prizloncabtagene autoleucel targets and binds to CD19- and CD20-expressing tumor B cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.",
  "synonyms": [
    "autologous anti-CD19/anti-CD20 CAR T cells EXP039",
    "autologous anti-CD19/CD20 CAR-T cells C-CAR039",
    "autologous CD19/CD20-targeting CAR T cells EXP039",
    "autologous CD19/CD20-targeting CAR-T cells EXP039"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/prizloncabtagene-autoleucel/"
}